Eric W Christensen1,2, Alicen Burns Spaulding2, William F Pomputius3, Steven P Grapentine4. 1. University of Minnesota, College of Continuing and Professional Studies, Health Services Management, St Paul. 2. Children's Minnesota Research Institute, Minneapolis. 3. Children's Minnesota, Division of Infectious Disease and Immunology, Minneapolis. 4. Department of Pharmacy, Children's Minnesota, Minneapolis.
Abstract
BACKGROUND: Hospital practice patterns vary for switching from intravenous to oral antibiotics for community-acquired pneumonia in pediatric patients, but it is unknown how these practice patterns affect hospital lengths of stay and costs. METHODS: We conducted a retrospective study of 78673 pediatric patients (aged 3 months to 17 years) hospitalized for community-acquired pneumonia. Analyses were performed with data from the Pediatric Health Information System between 2007 and 2016, including discharge data from 48 freestanding children's hospitals. Patients who received antibiotics used to treat aspiration pneumonia and patients with a complex chronic condition were excluded to focus the study on uncomplicated cases. We modeled hospital practice patterns using hospital-level averages for the last day of service on which patients received antibiotics intravenously or first day of service on which patients received antibiotics orally. RESULTS: We found that a 1-day decrease in the hospital-level average last day of service on which a patient received antibiotics intravenously reduced the average length of stay by 0.58 day (95% confidence interval [CI], -0.69 to -0.47 day) and average cost by $1332 (95% CI, -$2363 to -$300). Results were similar when hospital practice patterns were modeled using the average first day of service on which a patient received antibiotics orally. These reductions in lengths of stay and costs were not associated with a difference in 30-day readmission rates. CONCLUSIONS: Given the reductions in lengths of stay and costs without sacrificing patient outcomes (readmissions), antimicrobial stewardship programs could target provider education on the duration of intravenous antibiotic therapy as a way to reduce resource utilization.
BACKGROUND: Hospital practice patterns vary for switching from intravenous to oral antibiotics for community-acquired pneumonia in pediatric patients, but it is unknown how these practice patterns affect hospital lengths of stay and costs. METHODS: We conducted a retrospective study of 78673 pediatric patients (aged 3 months to 17 years) hospitalized for community-acquired pneumonia. Analyses were performed with data from the Pediatric Health Information System between 2007 and 2016, including discharge data from 48 freestanding children's hospitals. Patients who received antibiotics used to treat aspiration pneumonia and patients with a complex chronic condition were excluded to focus the study on uncomplicated cases. We modeled hospital practice patterns using hospital-level averages for the last day of service on which patients received antibiotics intravenously or first day of service on which patients received antibiotics orally. RESULTS: We found that a 1-day decrease in the hospital-level average last day of service on which a patient received antibiotics intravenously reduced the average length of stay by 0.58 day (95% confidence interval [CI], -0.69 to -0.47 day) and average cost by $1332 (95% CI, -$2363 to -$300). Results were similar when hospital practice patterns were modeled using the average first day of service on which a patient received antibiotics orally. These reductions in lengths of stay and costs were not associated with a difference in 30-day readmission rates. CONCLUSIONS: Given the reductions in lengths of stay and costs without sacrificing patient outcomes (readmissions), antimicrobial stewardship programs could target provider education on the duration of intravenous antibiotic therapy as a way to reduce resource utilization.
Authors: Laura S Gold; Ryan N Hansen; Donald L Patrick; Ashley Tabah; Sonya L Heltshe; Patrick A Flume; Christopher H Goss; Natalie E West; Don B Sanders; Donald R VanDevanter; Larry Kessler Journal: J Cyst Fibros Date: 2022-03-14 Impact factor: 5.527
Authors: Jillian M Cotter; Matt Hall; Sonya Tang Girdwood; John R Stephens; Jessica L Markham; James C Gay; Samir S Shah Journal: J Hosp Med Date: 2021-02 Impact factor: 2.960